It remains to be assessed if B-ALL cells are dependent on RUNX1, but its requirement for the survival of early mouse B-cell progenitors suggests that its inhibition may represent a therapeutic opportunity25. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.